Q4 2025 · 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLCholdings as filed
Filed 2026-02-12 · accession 0001420506-26-000321
$720.1M
Reported value
68
Positions
2025-12-31
Period end
The Brief · SILVERARC CAPITAL MANAGEMENT, LLC · Q4 2025
AI · grounded in 13F
Silverarc Capital Management, LLC closed its position in RNAGBP for a reduction of $36.8M. The fund also exited positions in AKRO and UTHR, reducing exposure by $30.6M and $25.1M respectively. On the buy side, the manager established new positions in IMNM for $24.2M and QURE for $17.2M. Additionally, the fund increased its stake in CELC by 322.9%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA | $56.9M | 7.91% | 422,193 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $44.2M | 6.14% | 1,245,254 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $40.7M | 5.66% | 1,738,821 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $39.2M | 5.44% | 2,427,118 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $37.4M | 5.20% | 375,132 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $31.3M | 4.35% | 311,430 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $30.9M | 4.29% | 750,136 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $28.6M | 3.97% | 1,023,122 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $24.3M | 3.38% | 82,465 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $24.2M | 3.36% | 1,126,210 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $21.6M | 3.01% | 9,840,041 | Common | SOLE |
| N90064901 | QURE | UNIQURE NV | $17.2M | 2.40% | 720,800 | CALL | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $16.1M | 2.24% | 1,029,066 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $15.1M | 2.09% | 357,558 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $15.0M | 2.08% | 361,158 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $14.6M | 2.02% | 135,950 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $13.5M | 1.88% | 642,899 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $13.3M | 1.84% | 75,412 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $12.4M | 1.72% | 71,256 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $11.5M | 1.59% | 458,203 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $10.8M | 1.51% | 348,569 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $10.5M | 1.46% | 49,228 | Common | SOLE |
| 717081103 | PFE | PFIZER INC | $10.4M | 1.45% | 419,134 | Common | SOLE |
| 08205P209 | BNTC | BENITEC BIOPHARMA INC | $9.9M | 1.37% | 731,717 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $9.5M | 1.32% | 524,436 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $9.4M | 1.30% | 91,914 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $9.1M | 1.27% | 1,116,604 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $6.9M | 0.95% | 148,787 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $6.8M | 0.94% | 541,240 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $6.6M | 0.92% | 2,135,722 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $6.2M | 0.85% | 187,737 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $6.1M | 0.85% | 617,608 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $6.1M | 0.85% | 506,242 | Common | SOLE |
| 157085101 | CERS | CERUS CORP | $5.8M | 0.81% | 2,814,383 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $5.6M | 0.78% | 1,051,343 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $5.4M | 0.76% | 117,485 | Common | SOLE |
| M25722105 | CGEN | COMPUGEN LTD | $5.3M | 0.74% | 3,479,805 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $5.2M | 0.72% | 191,074 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $5.2M | 0.72% | 206,280 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $4.9M | 0.68% | 1,317,584 | Common | SOLE |
| 483497903 | KALV | KALVISTA PHARMACEUTICALS INC | $4.7M | 0.65% | 290,600 | CALL | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $4.5M | 0.62% | 394,650 | Common | SOLE |
| 359616909 | FULC | FULCRUM THERAPEUTICS INC | $4.4M | 0.62% | 391,900 | CALL | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $4.0M | 0.55% | 303,939 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $3.8M | 0.53% | 1,994,224 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $3.6M | 0.49% | 157,323 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $3.5M | 0.49% | 307,540 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $3.4M | 0.48% | 94,983 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $3.4M | 0.47% | 398,167 | Common | SOLE |
| 00289Y206 | ABEO | ABEONA THERAPEUTICS INC | $3.3M | 0.46% | 627,738 | Common | SOLE |
| 872381108 | TELA | TELA BIO INC | $3.1M | 0.43% | 2,647,512 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $3.0M | 0.42% | 126,047 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $3.0M | 0.41% | 36,124 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $2.7M | 0.37% | 34,589 | Common | SOLE |
| 90400D908 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $2.5M | 0.35% | 110,000 | CALL | SOLE |
| 65343E207 | NXTC | NEXTCURE INC | $2.5M | 0.35% | 176,057 | Common | SOLE |
| 05479K106 | ELUT | ELUTIA INC | $1.9M | 0.26% | 2,751,314 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $1.7M | 0.24% | 41,460 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $1.6M | 0.23% | 385,974 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $1.4M | 0.20% | 357,387 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $1.0M | 0.14% | 42,052 | Common | SOLE |
| 75041J101 | RADX | RADIOPHARM THERANOSTICS LTD | $978,259 | 0.14% | 187,406 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $750,000 | 0.10% | 100,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $535,999 | 0.07% | 515,384 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $293,054 | 0.04% | 9,659 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $239,954 | 0.03% | 102,108 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $204,580 | 0.03% | 106,000 | Common | SOLE |
| 77313F114 | RCKTW | ROCKET PHARMACEUTICALS INC | $2,547 | 0.00% | 104,828 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.